Teva VP Ika Abravanel resigns
The lipid-based products developer held the IPO at $14 per share, below its target of $16-18, but the share price rose 30% on Friday.
Enzymotec Ltd. (Nasdaq: ENZY) has raised a net $63.5 million in its Nasdaq IPO on Thursday, after the underwriters exercised their over-allotment options in full. The exercise of options for 661,800 shares boosted the offering to 5,073,800 shares.
Enzymotec, a developer of lipid-based products and solutions for the nutritional and healthcare markets, held the IPO at $14 per share, below its target range of $16-18, but the share price jumped 29.7% on Friday from $14.10 to $18.16.
Enzymotec will use the proceeds to meet its anticipated increased working capital requirements resulting from the expected growth in its business and for other general corporate purposes.
Enzymotec has developed a proprietary method for processing fatty acids (lipids). The nutritional supplements developed on the basis of its method are sold under leading international nutritional supplements labels, as well as under its own label. In the US, the company also sells nutritional supplements, backed by clinical trials, for special indications, such as high cholesterol, heart disease, and memory improvement.
Enzymotec was founded in 1998 at Naiot Venture Accelerator in Yokne'am, on the basis of research by Dr. Sobhi Basheer. It is now based in Migdal Ha'Emek and its CEO is Ariel Katz.
In the first half of 2013, the company had sales of $28.7 million, 84% more than in the corresponding period in 2012, and posted a net profit of $4.7 million, which compares with $845,000 for the corresponding period, and $4.8 million for 2012 as a whole.
Enzymotec is owned by Galam Group Ltd. (Kibbutz Ma'anit), XT Investments Ltd. (formerly Ofer Hi-Tech), GlenRock Israel, Millennium Material Technologies Fund, and Mexico's Arancia Industrial SA de CV.
Published by Globes [online], Israel business news - www.globes-online.com - on September 29, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.